Form 4: Atlas Venture Funds Divest Generation Bio Stake Post-Merger

Atlas Venture entities report the disposal of all Generation Bio Co. common stock following the company's merger with XOMA Royalty Corporation's subsidiary.

Summary

• Atlas Venture Fund X, L.P. and related entities (Atlas Venture Associates X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., and Atlas Venture Associates Opportunity I, LLC) reported the disposal of their beneficial ownership in Generation Bio Co. (GBIO).
• The disposal occurred on February 9, 2026, as a result of Generation Bio Co. merging with XRA 7 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation.
• Shareholders of Generation Bio Co. received a purchase price of $4.2913 in cash per share and one non-tradeable contingent value right (CVR) per share.
• The CVR represents the right to receive certain contingent payments in cash, with an estimated maximum contingent consideration of $25.01 per CVR.
• Atlas Venture Fund X, L.P. directly disposed of 711,193 shares of Common Stock.
• Atlas Venture Opportunity Fund I, L.P. indirectly disposed of 116,693 shares of Common Stock.
• AVAO I LP indirectly disposed of 60 shares of Common Stock.
• Following these transactions, the reporting persons hold 0 shares of Generation Bio Co. common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive event for the former shareholders of Generation Bio Co., as it represents a completed exit with both immediate cash and potential future upside via CVRs, though the CVRs introduce uncertainty.

Positives

• Generation Bio Co. shareholders received an upfront cash payment of $4.2913 per share.
• Shareholders also received a contingent value right (CVR) with an estimated maximum value of $25.01 per CVR, offering potential future upside.
• The merger provides a clear exit strategy for existing shareholders, including the reporting Atlas Venture entities.

Negatives

• Generation Bio Co. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of XOMA Royalty Corporation.
• The contingent value rights (CVRs) are non-tradeable, limiting liquidity for the contingent payments.
• The actual value of the CVRs is contingent and not guaranteed to reach the estimated maximum.

Risks

• The contingent value rights (CVRs) are non-tradeable, meaning their value cannot be realized until the contingent payments are made, if at all.
• The estimated maximum contingent consideration of $25.01 per CVR is not guaranteed and depends on future events and conditions outlined in the contingent value rights agreement.

Future Outlook

The filing indicates that Generation Bio Co. has become a wholly-owned subsidiary of XOMA Royalty Corporation, and former shareholders now hold non-tradeable contingent value rights (CVRs) which represent the right to receive future contingent payments.

Management Comments

• Ommer Chohan, Chief Financial Officer, signed on behalf of Atlas Venture Fund X, L.P., Atlas Venture Associates X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., and Atlas Venture Associates Opportunity I, LLC.

Industry Context

StockSavvy.ai notes that the acquisition of Generation Bio Co. by XOMA Royalty Corporation is consistent with ongoing consolidation trends in the biotechnology and pharmaceutical sectors, where larger entities often acquire smaller, innovative companies to expand pipelines or gain access to specific technologies. The use of contingent value rights (CVRs) as part of the merger consideration is a common mechanism in biotech M&A, allowing buyers to defer a portion of the purchase price and link it to the achievement of future clinical or regulatory milestones, thereby sharing risk with selling shareholders.

Comparison to Industry Standards

• StockSavvy.ai observes that the merger consideration structure, combining an upfront cash payment with contingent value rights (CVRs), is a frequently employed strategy in the life sciences industry. For instance, similar structures have been seen in transactions like Sanofi's acquisition of Kadmon Holdings, where CVRs were tied to the approval of specific drug candidates, or Bristol Myers Squibb's acquisition of MyoKardia. The $4.2913 cash component provides immediate value, while the CVR, with an estimated maximum of $25.01, offers potential for significant additional returns, aligning with industry practices that incentivize successful post-merger development.

Related Party Transactions

• The merger transaction involved Atlas Venture entities, which were 10% owners and had a director relationship with Generation Bio Co., making it a transaction with a significant stakeholder.

Stakeholder Impact

• Shareholders (former Generation Bio Co.): Received cash and non-tradeable contingent value rights (CVRs) in exchange for their shares.
• Generation Bio Co.: Ceased to be an an independent public entity and became a wholly-owned subsidiary of XOMA Royalty Corporation.

Next Steps

• Realization of contingent payments from the non-tradeable CVRs, subject to the terms and conditions of the contingent value rights agreement.

Key Dates

Keywords

Generation Bio Co., GBIO, XOMA Royalty Corporation, Merger, Acquisition, Contingent Value Right, CVR, Insider Trading, Form 4, Beneficial Ownership, Atlas Venture, Biotechnology, Pharmaceuticals